Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730405 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis
A Phase 2 study, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 582
- Enrollment target
NCT00730405 is a Phase 2 study that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 582 participants.
The verdict
NCT00730405, a Phase 2 study, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 582 participants
- Enrollment target
Study Summary
Phase 2 study to examine how the study drug works and its side effects in subjects with toenail fungus.
Interventions
- DRUG Albaconazole 100mg
- DRUG Albaconazole 200mg
- DRUG Albaconazole 400mg
- DRUG Placebo 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 582 participants |
| Start Date | 2008-07-16 |
| Est. Completion | 2010-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00730405
The ClinicalTrials.gov registry entry for NCT00730405 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 582 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stiefel, a GSK Company, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Albaconazole 100mg is the first listed.
NCT00730405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00730405 about?
NCT00730405 is a clinical study titled "Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis". Phase 2 study to examine how the study drug works and its side effects in subjects with toenail fungus.
What is the current status of trial NCT00730405?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 582 participants. The study started on 2008-07-16. Estimated completion is 2010-02-19.
What interventions are being tested in trial NCT00730405?
The interventions under investigation include: Albaconazole 100mg (DRUG), Albaconazole 200mg (DRUG), Albaconazole 400mg (DRUG), Placebo 400 mg (DRUG).
Who is sponsoring clinical trial NCT00730405?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.